Moss Jason M, Choi Clara Y H, Adler John R, Soltys Scott G, Gibbs Iris C, Chang Steven D
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305, USA.
Neurosurgery. 2009 Jul;65(1):79-85; discussion 85. doi: 10.1227/01.NEU.0000348015.51685.D2.
Stereotactic radiosurgery has been used for nearly 2 decades to treat hemangioblastomas, particularly those that are in surgically inaccessible locations or that are multiple, as is common in von Hippel-Lindau disease. There is a paucity of long-term published radiosurgical treatment outcomes, particularly for spinal lesions, in a large patient population. The purpose of this study was to provide a long-term retrospective evaluation of radiosurgical hemangioblastoma treatment effectiveness, with a special emphasis on the relatively recent use of frameless, image-guided radiosurgery in the treatment of spinal lesions.
From 1991 to 2007, 92 hemangioblastomas in 31 patients, 26 with von Hippel-Lindau disease, were treated with radiosurgery (27 tumors treated with frame-based linear accelerator radiosurgery, and 67 tumors were treated with CyberKnife radiosurgery). The mean patient age was 41 years (range, 18-81 years). The radiation dose to the tumor periphery averaged 23.4 Gy (range, 12-40 Gy). The mean tumor volume was 1.8 cm (range, 0.058-65.4 cm). Tumor response was evaluated in serial, contrast-enhanced, computed tomographic, and magnetic resonance imaging scans.
Clinical and radiographic follow-up data were available for 82 hemangioblastoma tumors. Only 13 (16%) of the treated hemangioblastomas progressed, whereas 18 tumors (22%) showed radiographic regression, and 51 tumors (62%) remained unchanged in size. With median follow-up of 69 months (range, 5-164 months), the actuarial local control rates at 36 and 60 months were 85% and 82%, respectively. Radiosurgery improved lesion-associated symptoms in 36 of 41 tumors. During the follow-up period, 9 patients died of causes unrelated to the progression of their treated hemangioblastomas, and 5 patients developed radiation necrosis.
Stereotactic radiosurgery is safe and effective in the treatment of hemangioblastomas and is an attractive alternative to surgery for patients, including those with von Hippel-Lindau disease.
立体定向放射外科已用于治疗血管母细胞瘤近20年,尤其适用于那些手术难以触及或多发的血管母细胞瘤,这在冯·希佩尔-林道病中很常见。在大量患者群体中,长期公布的放射外科治疗结果很少,尤其是对于脊柱病变。本研究的目的是对放射外科治疗血管母细胞瘤的有效性进行长期回顾性评估,特别强调在治疗脊柱病变中相对较新使用的无框架、图像引导放射外科。
1991年至2007年,31例患者中的92个血管母细胞瘤接受了放射外科治疗(27个肿瘤采用基于框架的直线加速器放射外科治疗,67个肿瘤采用射波刀放射外科治疗)。患者平均年龄为41岁(范围18 - 81岁)。肿瘤周边的辐射剂量平均为23.4 Gy(范围12 - 40 Gy)。平均肿瘤体积为1.8 cm(范围0.058 - 65.4 cm)。通过连续的、增强对比的计算机断层扫描和磁共振成像扫描评估肿瘤反应。
82个血管母细胞瘤肿瘤有临床和影像学随访数据。仅13个(16%)接受治疗的血管母细胞瘤进展,而18个肿瘤(22%)显示影像学退缩,51个肿瘤(62%)大小保持不变。中位随访69个月(范围5 - 164个月),36个月和60个月时的精算局部控制率分别为85%和82%。放射外科改善了41个肿瘤中36个与病变相关的症状。在随访期间,9例患者死于与所治疗的血管母细胞瘤进展无关的原因,5例患者发生放射性坏死。
立体定向放射外科治疗血管母细胞瘤安全有效,对于包括冯·希佩尔-林道病患者在内的患者是一种有吸引力的手术替代方案。